(Q38299472)

1 September 2017

1 reference

title

Neuroprotection in Experimental Autoimmune Encephalomyelitis and Progressive Multiple Sclerosis by Cannabis-Based Cannabinoids (English)

1 reference

experimental autoimmune encephalomyelitis

1 September 2017

0 references

0 references

1 reference

4

Gavin Giovannoni

1 reference

1 September 2017

Gareth Pryce

1

1 reference

1 September 2017

Dieter R Riddall

series ordinal

2

1 reference

1 September 2017

David L Selwood

series ordinal

3

1 reference

1 September 2017

David Baker

series ordinal

5

1 reference

1 September 2017

publication date

24 December 2014

1 reference

Journal of Neuroimmune Pharmacology

1 September 2017

published in

1 reference

1 September 2017

volume

10

1 reference

1 September 2017

issue

2

1 reference

1 September 2017

page(s)

281-292

1 reference

Practical guide to the induction of relapsing progressive experimental autoimmune encephalomyelitis in the Biozzi ABH mouse

1 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Lesional-targeting of neuroprotection to the inflammatory penumbra in experimental multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Publication guidelines for refereeing and reporting on animal use in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Experimental autoimmune encephalomyelitis is a good model of multiple sclerosis if used wisely

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabinoids control spasticity and tremor in a multiple sclerosis model

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Critical appraisal of animal models of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

The biology that underpins the therapeutic potential of cannabis-based medicines for the control of spasticity in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Blockade of monoacylglycerol lipase inhibits oligodendrocyte excitotoxicity and prevents demyelination in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Heterogeneity in the composition of marijuana seized in California

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Δ⁹-tetrahydrocannabinol (Δ⁹-THC) exerts a direct neuroprotective effect in a human cell culture model of Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabis use in patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Patterns of cannabis use among patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

The perceived effects of smoked cannabis on patients with multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Smoked cannabis for spasticity in multiple sclerosis: a randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

A role for CB2 receptors in anandamide signalling pathways involved in the regulation of IL-12 and IL-23 in microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabinoid-mediated neuroprotection, not immunosuppression, may be more relevant to multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Influence of cannabidiol on delta-9-tetrahydrocannabinol effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabinoids ameliorate disease progression in a model of multiple sclerosis in mice, acting preferentially through CB1 receptor-mediated anti-inflammatory effects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

The endocannabinoid anandamide protects neurons during CNS inflammation by induction of MKP-1 in microglial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Neuroprotective effect of (-)Delta9-tetrahydrocannabinol and cannabidiol in N-methyl-D-aspartate-induced retinal neurotoxicity: involvement of peroxynitrite

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Motor effects of the non-psychotropic phytocannabinoid cannabidiol that are mediated by 5-HT1A receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Soluble guanylyl cyclase activator YC-1 protects white matter axons from nitric oxide toxicity and metabolic stress, probably through Na(+) channel inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Biomarker report from the phase II lamotrigine trial in secondary progressive MS - neurofilament as a surrogate of disease progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Neuroprotection without immunomodulation is not sufficient to reduce first relapse severity in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Voltage-gated sodium (NaV) channel blockade by plant cannabinoids does not confer anticonvulsant effects per se.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

International Union of Pharmacology. XXVII. Classification of cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Lamotrigine for neuroprotection in secondary progressive multiple sclerosis: a randomised, double-blind, placebo-controlled, parallel-group trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabinoid influence on cytokine profile in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Immunomodulatory effects of orally administered cannabinoids in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabidiol inhibits pathogenic T cells, decreases spinal microglial activation and ameliorates multiple sclerosis-like disease in C57BL/6 mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

A double-blind, randomized, placebo-controlled, parallel-group study of THC/CBD oromucosal spray in combination with the existing treatment regimen, in the relief of central neuropathic pain in patients with multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Evidence for a two-stage disability progression in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Delta 9-tetrahydrocannabinol: a novel treatment for experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

The nonpsychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabidiol protects oligodendrocyte progenitor cells from inflammation-induced apoptosis by attenuating endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabidiol provides long-lasting protection against the deleterious effects of inflammation in a viral model of multiple sclerosis: a role for A2A receptors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabidiol: an overview of some pharmacological aspects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Safinamide and flecainide protect axons and reduce microglial activation in models of multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

CB1 receptor antagonism/inverse agonism increases motor system excitability in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

[3H]Batrachotoxinin A 20-alpha-benzoate binding to sodium channels in rat brain: characterization and pharmacological significance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Control of spasticity in a multiple sclerosis model is mediated by CB1, not CB2, cannabinoid receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabinoids inhibit neurodegeneration in models of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Control of spasticity in a multiple sclerosis model using central nervous system-excluded CB1 cannabinoid receptor agonists

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Therapeutic potential of a novel cannabinoid agent CB52 in the mouse model of experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabinoid CB1 receptors regulate neuronal TNF-α effects in experimental autoimmune encephalomyelitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Association between a genetic variant of type-1 cannabinoid receptor and inflammatory neurodegeneration in multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

A tale of two cannabinoids: the therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabidiol targets mitochondria to regulate intracellular Ca2+ levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Genetic background can result in a marked or minimal effect of gene knockout (GPR55 and CB2 receptor) in experimental autoimmune encephalomyelitis models of multiple sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabidiol displays unexpectedly high potency as an antagonist of CB1 and CB2 receptor agonists in vitro

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Divergent effects of cannabidiol on the discriminative stimulus and place conditioning effects of Delta(9)-tetrahydrocannabinol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Interactions between THC and cannabidiol in mouse models of cannabinoid activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Genetic deletion of Fatty Acid Amide Hydrolase results in improved long-term outcome in chronic autoimmune encephalitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Medicinal cannabis: is delta9-tetrahydrocannabinol necessary for all its effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Summary of evidence-based guideline: complementary and alternative medicine in multiple sclerosis: report of the guideline development subcommittee of the American Academy of Neurology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11481-014-9575-8

Excitotoxicity in a chronic model of multiple sclerosis: Neuroprotective effects of cannabinoids through CB1 and CB2 receptor activation

21 January 2018

1 reference

12 December 2020

Cannabinoids in multiple sclerosis (CAMS) study: safety and efficacy data for 12 months follow up.

1 reference

12 December 2020

Sodium channels as molecular targets in multiple sclerosis.

1 reference

12 December 2020

Complementary and alternative medicine use and nutrient intake among individuals with multiple sclerosis in the United States

1 reference

12 December 2020

Effect of marijuana use on outcomes in traumatic brain injury

1 reference

12 December 2020

The problem with repurposing: Is there really an alternative to Big Pharma for developing new drugs for multiple sclerosis?

1 reference

12 December 2020

A Reversible and Selective Inhibitor of Monoacylglycerol Lipase Ameliorates Multiple Sclerosis

1 reference

12 December 2020

The (AAT)n repeat of the cannabinoid CB1 receptor gene influences disease progression in relapsing multiple sclerosis

1 reference

12 December 2020

Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997.

1 reference

12 December 2020

Pre- and postsynaptic type-1 cannabinoid receptors control the alterations of glutamate transmission in experimental autoimmune encephalomyelitis

1 reference

12 December 2020

Delayed treatment with cannabidiol has a cerebroprotective action via a cannabinoid receptor-independent myeloperoxidase-inhibiting mechanism

1 reference

12 December 2020

Disease modifying drugs in multiple sclerosis: mechanisms of action and new drugs in the horizon

1 reference

12 December 2020

Direct suppression of CNS autoimmune inflammation via the cannabinoid receptor CB1 on neurons and CB2 on autoreactive T cells

1 reference

12 December 2020

Multiple sclerosis and extract of cannabis: results of the MUSEC trial.

1 reference

12 December 2020

Regulation of chronic relapsing experimental allergic encephalomyelitis by endogenous and exogenous glucocorticoids

1 reference

12 December 2020

10.1007/S11481-014-9575-8

Identifiers

DOI

1 reference

Dimensions Publication ID

1 September 2017

1024433740

0 references

1 reference